GAU 1815

71435

Dkt. 0575/50659/JPW/JML

SEP 1 7 1997 STATES PATENT AND TRADEMARK OFFICE SEP 2 3 1997:

Applicants : David Baltimore et al.

GROUP 1800

Ser 130 : 08/813,323

Filed : March 10, 1997

Art Unit: 1815

r Le

For : TRUNCATED CRAF1 INHIBITS CD40 SIGNALING

1185 Avenue of the Americas New York, New York 10036

September 16, 1997

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following, which are listed on Form PTO-1449 (Exhibit 1). Copies of the disclosures listed below as items 1-4 are attached hereto as Exhibits 2-5, respectively.

- Goeddel, David V. et al., Tumor Necrosis Factor Receptor-Associated Factors, International Publication No. WO 95/33051 (Exhibit 2);
- 2. Cheng, Genhong et al. (1995) Involvement of CRAF1, a Relative of TRAF, in CD40 Signaling, Science 267: 1494-1498 (Exhibit 3);
- 3. Hu, Hong Ming et al. (1994) A Novel RING Finger Protein Interacts with the Cytoplasmic Domain of CD40, J. Bio. Chem. 269: 30069-30072 (Exhibit 4);

David Baltimore et al. U.S. Serial No.: 08/813,323 Filed: March 10, 1997 Page 2

Interacts with the Cytoplasmic Domain of CD40, J. Bio. Chem. 269: 30069-30072 (Exhibit 4);

4. Mosialos, George et al. (1995) The Epstein-Barr Virus Transforming Protein LMP1 Engages Signaling Proteins for the Tumor Necrosis Factor Receptor Family, Cell 80:389-399 (Exhibit 5);

Applicants maintain that none of those above-listed references citable as a reference against the subject application disclose or suggest the invention now being claimed.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

David Baltimore et al. U.S. Serial No.: 08/813,323 Filed: March 10, 1997 Page 3

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. If any such fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Assistant Commissioner for Patents Washington, D.C. 20231.

John P. White Da

Reg. No. 28,678

vate

Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036

(212) 278-0400

John R. White